--- title: Theranos: how a $9 billion blood-testing startup turned out to be a fraud | RGM® url: https://realgrowthmatters.com/learn/case-studies/theranos-fraud-collapse-cautionary/ updated: 2026-06-10 source_html: https://realgrowthmatters.com/learn/case-studies/theranos-fraud-collapse-cautionary/ --- - **Story:** Elizabeth Holmes founded Theranos in 2003. By 2014, $9B valuation. October 2015: Wall Street Journal exposed that the technology fundamentally didn't work. Collapsed by 2018. Holmes convicted of fraud in 2022, sentenced to ~11 years. Investors lost ~$700M. - **Why it matters:** Theranos is the defining startup-fraud case. The structural diligence failures (non-technical board, no independent technical validation, NDA-enforced internal silence) are preventable in retrospect. - **Takeaway:** Technical claims contradicting established science require independent technical validation. - **Takeaway:** Boards on technology companies must include technical expertise, not just prestige. - **Takeaway:** NDAs preventing employees from discussing safety or quality issues are operational red flags. ## Theranos — the four-step story S Situation Theranos claimed revolutionary blood-testing technology Elizabeth Holmes founded Theranos in 2003. By 2014, $9B valuation. October 2015: Wall Street Journal exposed that the technology fundamentally didn't work. Collapsed by 2018. Holmes convicted of fraud T Task Validate technical claims through independent testing Theranos is the defining startup-fraud case. The structural diligence failures (non-technical board, no independent technical validation, NDA-enforced internal silence) are preventable in retrospect. A Action Failed: board lacked expertise; investors didn't do technical diligence; employees were silenced via NDAs Technical claims contradicting established science require independent technical validation. R Result $700M+ investor losses, Holmes convicted 2022, ~11-year sentence Boards on technology companies must include technical expertise, not just prestige. ## Theranos at a glance $0B Peak valuation (2014) Pre-collapse Source: PitchBook ~$0M Investor losses Across all backers Source: Court records 0 WSJ exposé John Carreyrou reporting Source: WSJ archive 0 Holmes convicted 4 counts of fraud Source: Federal court records ~0+ yrs Sentence Federal prison Source: DOJ records 0 Cautionary tale Defining startup-fraud case Source: Industry curricula #### Quick facts CompanyTheranos (defunct 2018) FounderElizabeth Holmes Founded2003, Palo Alto, California Peak valuation$9B (2014) Total capital raised~$700M+ WSJ exposéOctober 16, 2015 (John Carreyrou) SEC fraud charges2018 (Holmes and Sunny Balwani) Holmes conviction2022 (4 counts of fraud); sentenced to ~11 years **Honest note** The Theranos collapse is one of the most-documented startup-fraud cases in modern history. John Carreyrou's book “Bad Blood” (2018), the Hulu series “The Dropout,” multiple HBO documentaries, and extensive court proceedings have laid out the facts in detail. The basic story (the technology fundamentally didn't work; Holmes lied repeatedly about capabilities; investors and board members didn't do adequate technical due diligence) is uncontested. ## The pitch and the rise Elizabeth Holmes founded Theranos at 19 after dropping out of Stanford. The pitch was revolutionary: blood-testing technology that could perform hundreds of medical tests from a single drop of blood obtained through a finger-prick. Traditional blood tests required multiple vials of blood and specialized lab equipment costing tens of thousands of dollars per test panel. Theranos claimed it would democratize medical testing. Holmes raised approximately $700 million from major investors including Rupert Murdoch, the Walton family, Tim Draper (early-stage), Larry Ellison, and various other high-profile backers. The board included Henry Kissinger, George Shultz, James Mattis, Sam Nunn, William Perry, and other former cabinet secretaries and military officers. The board was deliberately heavy on prestige and light on technical-medical expertise. By 2014, Theranos was valued at $9 billion. Holmes was on every magazine cover — Forbes, Fortune, Time. ## What was actually happening The technology fundamentally didn't work. Theranos's proprietary “Edison” blood-testing devices could perform only a handful of tests reliably (not the hundreds Theranos claimed). The actual blood tests Theranos was selling to consumers at Walgreens locations and other partners were being run primarily on standard third-party laboratory equipment (Siemens, Bio-Rad, etc.) using larger conventional blood draws — not the proprietary finger-prick technology the marketing described. Internal Theranos employees who raised concerns about test reliability were systematically fired, sued, or threatened with legal action. The company maintained an aggressive non-disclosure-agreement regime that prevented employees from discussing what was happening internally. Holmes and Sunny Balwani (COO and Holmes's partner) actively misrepresented the technology to investors, board members, and partners over a period of years. ## The collapse On October 16, 2015, the Wall Street Journal's John Carreyrou published the first in a series of investigative reports that exposed the underlying technology failures and the misrepresentations. The reporting was based on testimony from former Theranos employees and detailed technical analysis. The story compounded over the following weeks and months as more former employees came forward. The cascade was unrelenting. Walgreens terminated the partnership. The FDA and CMS issued enforcement actions. The SEC began investigating. The board (much of which had been kept in the dark by Holmes) began turning. By 2018, Theranos was effectively dissolved. The SEC charged Holmes and Balwani with fraud in 2018; Holmes settled with the SEC while denying wrongdoing. Criminal charges followed. Elizabeth Holmes was convicted in January 2022 on four counts of defrauding investors and was sentenced to approximately 11 years in federal prison. Sunny Balwani was convicted separately on 12 counts and received a longer sentence. The investors who had backed Theranos lost essentially all the capital they had invested — approximately $700 million collectively. ## How RGM thinks about due-diligence failures When clients ask about due-diligence and investment-decision failures, the Theranos case is the defining example. The structural failure modes were preventable: a board heavy on prestige and light on technical expertise, investor due-diligence that didn't include independent technical validation, employee NDA enforcement that prevented internal whistleblowing, journalist credentials that weren't engaged until John Carreyrou's reporting forced the issue. The honest framework: technical claims that contradict established science require independent technical validation, not founder pitch decks. Boards on fast-growing technology companies must include people who can evaluate technical claims, not just operate the business or contribute prestige. Employee NDAs that prevent discussion of safety or quality issues are operational red flags. We tell clients that diligence failures of the Theranos scale aren't usually caused by sophisticated deception — they're caused by structural diligence-process failures that any of multiple parties could have caught earlier. The Theranos case is widely studied because the diligence failures were predictable in retrospect. ## Frequently asked questions Did Elizabeth Holmes actually believe the technology worked? Disputed. Holmes's legal defense at trial argued she genuinely believed in the technology and was a victim of Sunny Balwani's influence. Prosecutors argued she actively misrepresented capabilities she knew didn't exist. The jury convicted her on multiple counts, suggesting they didn't fully accept her defense. The exact mental state is impossible to verify; the misrepresentations are documented regardless. How much did investors lose? Approximately $700 million collectively across all investors. Major investors included Rupert Murdoch (lost ~$125M), the Walton family (lost ~$150M+), Tim Draper (initial Series A; smaller absolute losses but reputational), and various others. Some investors recovered partial value through SEC settlement distributions, but the recoveries were small relative to the invested capital. Why didn't the board catch it earlier? The board was deliberately structured for prestige rather than technical expertise. Members like Henry Kissinger, George Shultz, James Mattis, and Sam Nunn brought political and military credibility but had no medical-device or biotechnology expertise. The board also wasn't given accurate technical information by Holmes and Balwani. The structural diligence failure — a non-technical board on a technology company — is one of the case's main lessons. ### Sources & references - [John Carreyrou — Bad Blood (book, 2018)](https://www.penguinrandomhouse.com/books/549478/bad-blood-by-john-carreyrou/) — Definitive book on the Theranos rise and fall. - [Wall Street Journal Theranos coverage](https://www.wsj.com/articles/theranos-1444851982) — Carreyrou's original investigative reporting. - [DOJ prosecution records](https://www.justice.gov/usao-ndca) — Federal court records from the Holmes and Balwani prosecutions. ## Related [#### All case studies The full case-study library.](/learn/case-studies/)[#### WeWork 2019 Adjacent narrative-vs-substance fundraising failure.](/learn/case-studies/wework-2019-ipo-failure-cautionary/)[#### Quibi 2020 Well-funded startup failure.](/learn/case-studies/quibi-2020-launch-failure-cautionary/)[#### Wells Fargo fake accounts Adjacent fraud-at-scale cautionary case.](/learn/case-studies/wells-fargo-fake-accounts-scandal/)